Read more at Financial Times.
Novo Nordisk faces US Senate grilling over price of weight loss drugs
Date: |
Topics
-
The Wall Street Journal - Business
The Price War in Weight-Loss Drugs Is Here
Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price tags of over $1,000 a month.3 days ago -
Financial Times - Business
US drug ‘gatekeepers’ face FTC antitrust lawsuit over insulin prices
Complaint alleges pharmacy benefit managers owned by CVS, Cigna and UnitedHealth are keeping prices high2 days ago -
CBS News - Top stories
Inside the thriving market for alternatives to brand-name weight loss drugs
High demand for weight-loss and diabetes drugs like Ozempic and Wegovy has led to a shortage in manufacturing. In the meantime, a market for cheaper, compounded drugs thrives.2 days ago -
CBS News - Top stories
As weight loss drugs explode in popularity, are online marketplaces safe?
Weight loss drugs are exploding in popularity, with 1 in 8 Americans saying they have tried medications like Ozempic and Wegovy to tackle everything from diabetes to weight loss, among other ...Yesterday -
MarketWatch - Business
FTC sues prescription-drug middlemen over insulin prices, says drugmakers are also ‘on notice’
Pharmacy-benefit managers owned by CVS, Cigna and UnitedHealth “artificially inflated” prices for lifesaving medications, regulator alleges.2 days ago -
The New York Times - Health
F.T.C. Accuses Drug Middlemen of Inflating Insulin Prices
The case takes aim at the major pharmacy benefit managers, agency officials said, claiming that they favored more expensive insulin products and forced patients to pay more.2 days ago -
The Wall Street Journal - Business
FTC Accuses Drug Middlemen of Inflating Insulin Prices
The Federal Trade Commission sued the drug middlemen that health plans use to keep a lid on drug spending, accusing the firms of inflating the price of insulin.2 days ago -
CNBC - Business
FTC sues drug middlemen for allegedly inflating insulin prices
The FTC suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group's Optum Rx, CVS Health's Caremark and Cigna's Express Scripts.Yesterday
More from Financial Times
-
Financial Times - World
Nurses in England reject government pay deal
RCN general secretary says ballot result shows members’ expectations are ‘far higher’ than 5.5% offer19 minutes ago -
Financial Times - World
France asks Brussels for extra delay on spending plans
Paris says it will submit road map on compliance with EU fiscal rules by October 3121 minutes ago -
Financial Times - World
Dear Kamala: a letter from Pennsylvania
You can’t have reconciliation without truth26 minutes ago -
Financial Times - World
India win Olympiad gold as new generation dominates in Budapest
Puzzle: find the win that the world No 3 missed1 hour ago - India -
Financial Times - World
Lessons for UK universities from the Australian experience
From Sydney to Manchester, higher education institutions need the benefit of a policy compact for the long term1 hour ago - United Kingdom